Cast


Ventrus Biosciences, Inc. (VTUS)

(NASDAQ: VTUS)

SUMMARY

 
 

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ventrus Biosciences, Inc. (“Ventrus” or the “Company”) (NASDAQ: VTUS).

The investigation focuses on whether the Company and its executives violated federal securities laws by issuing false and/or misleading statements and failing to disclose materially adverse facts concerning the Company’s lead product iferanserin (VEN 309) (“VEN 309”).

The Company described VEN 309 as a new chemical entity for the topical treatment of symptomatic internal hemorrhoids.  According to Ventrus, VEN 309 demonstrated good tolerability and no severe adverse events while showing statistically significant improvements in bleeding, itchiness, and pain in seven clinical studies between 1993 and 2003.  Moreover, the Company touted that the prior results from Phase II trials of VEN 309 demonstrated the product’s clinical efficacy.

However, Ventrus issued a press release on June 25, 2012 announcing that VEN 309 failed its Phase III trial, causing the Company to abandon further development of VEN 309, including any further attempt to obtain FDA approval.  In response to this news, the price of Ventrus common stock plummeted over 50%, to $5.02 per share, on June 25, 2012.

Take Action

If you invested in Ventrus stock or options between December 17, 2010 and June 25, 2012 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Ventrus’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

 
 

Request Information

 
  Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you. If you want to be a Lead Plaintiff or join
this action now, please click HERE.
Case:Ventrus Biosciences, Inc. (VTUS)
 
 
 
   
 
 

Case Details

Contact Counsel

Francis P. McConville
Richard W. Gonnello
Faruqi & Faruqi, LLP
369 Lexington Avenue 10th Floor
New York, NY 10017
Tel: (212) 983-9330
Email:  fmcconville@faruqilaw.com
rgonnello@faruqilaw.com

Send Information

If you have information regarding this case that you would
like to make available, please click here to contact us
about our investigation